These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 35590366)

  • 21. Evinacumab for the treatment of homozygous familial hypercholesterolemia.
    Gao Y; Zhang B; Yang J
    Expert Rev Clin Pharmacol; 2022 Feb; 15(2):139-145. PubMed ID: 35220876
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk.
    Gobeil É; Bourgault J; Mitchell PL; Houessou U; Gagnon E; Girard A; Paulin A; Manikpurage HD; Côté V; Couture C; Marceau S; Bossé Y; Thériault S; Mathieu P; Vohl MC; Tchernof A; Arsenault BJ
    Eur Heart J; 2024 Mar; 45(9):707-721. PubMed ID: 38243829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential association of plasma angiopoietin-like proteins 3 and 4 with lipid and metabolic traits.
    Mehta N; Qamar A; Qu L; Qasim AN; Mehta NN; Reilly MP; Rader DJ
    Arterioscler Thromb Vasc Biol; 2014 May; 34(5):1057-63. PubMed ID: 24626437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia.
    Ahmad Z; Banerjee P; Hamon S; Chan KC; Bouzelmat A; Sasiela WJ; Pordy R; Mellis S; Dansky H; Gipe DA; Dunbar RL
    Circulation; 2019 Aug; 140(6):470-486. PubMed ID: 31242752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Angiopoietin-Like 3 on Triglyceride Regulation, Glucose Homeostasis, and Diabetes.
    Christopoulou E; Elisaf M; Filippatos T
    Dis Markers; 2019; 2019():6578327. PubMed ID: 30944669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion.
    Wang Y; Gusarova V; Banfi S; Gromada J; Cohen JC; Hobbs HH
    J Lipid Res; 2015 Jul; 56(7):1296-307. PubMed ID: 25954050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A quantitative systems pharmacology modeling platform for evaluating triglyceride profiles in patients with high triglycerides receiving evinacumab.
    Khaksar Toroghi M; Bosley J; Powell LM; Zhang Y; Yang F; Pu X; Davis JD; Al-Huniti N
    CPT Pharmacometrics Syst Pharmacol; 2021 Nov; 10(11):1332-1342. PubMed ID: 34327869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ANGPTL3 Deficiency and Risk of Hepatic Steatosis.
    D'Erasmo L; Di Martino M; Neufeld T; Fraum TJ; Kang CJ; Burks KH; Di Costanzo A; Minicocci I; Bini S; Maranghi M; Pigna G; Labbadia G; Zheng J; Fierro D; Montali A; Ceci F; Catalano C; Davidson NO; Lucisano G; Nicolucci A; Arca M; Stitziel NO
    Circulation; 2023 Nov; 148(19):1479-1489. PubMed ID: 37712257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ANGPTL3 is a novel HDL component that regulates HDL function.
    Yang L; Wang Y; Xu Y; Li K; Yin R; Zhang L; Wang D; Wei L; Lang J; Cheng Y; Wang L; Ke J; Zhao D
    J Transl Med; 2024 Mar; 22(1):263. PubMed ID: 38462608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys.
    Gusarova V; Alexa CA; Wang Y; Rafique A; Kim JH; Buckler D; Mintah IJ; Shihanian LM; Cohen JC; Hobbs HH; Xin Y; Valenzuela DM; Murphy AJ; Yancopoulos GD; Gromada J
    J Lipid Res; 2015 Jul; 56(7):1308-17. PubMed ID: 25964512
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Pennisi G; Maurotti S; Ciociola E; Jamialahmadi O; Bertolazzi G; Mirarchi A; Bergh PO; Scionti F; Mancina RM; Spagnuolo R; Tripodo C; Boren J; Petta S; Romeo S
    Arterioscler Thromb Vasc Biol; 2024 May; 44(5):1086-1097. PubMed ID: 38385290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia.
    Kosmas CE; Bousvarou MD; Sourlas A; Papakonstantinou EJ; Peña Genao E; Echavarria Uceta R; Guzman E
    Clin Pharmacol; 2022; 14():49-59. PubMed ID: 35873366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Lipid-Modulating Effect of Tangeretin on the Inhibition of Angiopoietin-like 3 (ANGPTL3) Gene Expression through Regulation of LXRα Activation in Hepatic Cells.
    Chen PY; Chao TY; Hsu HJ; Wang CY; Lin CY; Gao WY; Wu MJ; Yen JH
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiopoietin-like 3 inhibition of endothelial lipase is not modulated by angiopoietin-like 8.
    Sylvers-Davie KL; Segura-Roman A; Salvi AM; Schache KJ; Davies BSJ
    J Lipid Res; 2021; 62():100112. PubMed ID: 34461133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ANGPTL3 as therapeutic target.
    Kersten S
    Curr Opin Lipidol; 2021 Dec; 32(6):335-341. PubMed ID: 34581310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiopoietin-like protein 3, an emerging cardiometabolic therapy target with systemic and cell-autonomous functions.
    Ruhanen H; Haridas PAN; Jauhiainen M; Olkkonen VM
    Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Dec; 1865(12):158791. PubMed ID: 32777482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carboxyl-terminal sequences in APOA5 are important for suppressing ANGPTL3/8 activity.
    Chen YQ; Yang Y; Zhen EY; Beyer TP; Li H; Wen Y; Ehsani M; Jackson N; Xie K; Jung H; Scheithauer JL; Kumari A; Birrane G; Russell AM; Balasubramaniam D; Liao Z; Siegel RW; Qian Y; Ploug M; Young SG; Konrad RJ
    Proc Natl Acad Sci U S A; 2024 Apr; 121(17):e2322332121. PubMed ID: 38625948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids.
    Chen YQ; Pottanat TG; Siegel RW; Ehsani M; Qian YW; Zhen EY; Regmi A; Roell WC; Guo H; Luo MJ; Gimeno RE; Van't Hooft F; Konrad RJ
    J Lipid Res; 2020 Aug; 61(8):1203-1220. PubMed ID: 32487544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase.
    Shimizugawa T; Ono M; Shimamura M; Yoshida K; Ando Y; Koishi R; Ueda K; Inaba T; Minekura H; Kohama T; Furukawa H
    J Biol Chem; 2002 Sep; 277(37):33742-8. PubMed ID: 12097324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic profiling of angiopoietin-like protein 3 and 4 inhibition: a drug-target Mendelian randomization analysis.
    Wang Q; Oliver-Williams C; Raitakari OT; Viikari J; Lehtimäki T; Kähönen M; Järvelin MR; Salomaa V; Perola M; Danesh J; Kettunen J; Butterworth AS; Holmes MV; Ala-Korpela M
    Eur Heart J; 2021 Mar; 42(12):1160-1169. PubMed ID: 33351885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.